Celldex Therapeutics (CLDX) has just been added to several Russell growth benchmarks, coinciding with updated long term Phase 2 data for barzolvolimab in angioedema, a combination that is drawing fresh attention to the stock.

The latest Russell index additions and the updated barzolvolimab data come after a strong period for Celldex Therapeutics, with a year to date share price return of 37.76% and a 1 year total shareholder return of 75.44%, suggesting momentum has been building despite a modest 1 day share price decline of 0.61%.

If you are looking for more ideas in a similar space, this could be a good moment to scan other healthcare related AI opportunities through the 40 healthcare AI stocks

With Celldex Therapeutics now in several Russell growth benchmarks and trading at a sizeable discount to analyst price targets, the key question is whether investors are still early or if the market is already pricing in future growth.

Preferred Price-to-Book of 6.4x: Is It Justified?

Celldex Therapeutics currently trades on a P/B of 6.4x, which sits well above both its peer group and the broader US biotech sector at the last close of $37.21.

The P/B ratio compares the market value of the equity to the accounting value of net assets, which can matter for early stage biopharma where earnings are not yet positive. For Celldex Therapeutics, a 6.4x P/B suggests investors are placing a high value on the company relative to its current balance sheet, even though it remains loss making.

Against that backdrop, the SWS DCF model and fair value checks present a different angle. The stock is described as trading at a 54.4% discount to an estimate of fair value, at $37.21 per share versus an assessed future cash flow value of $81.61. However, when compared to peers, the 6.4x P/B is described as expensive relative to both the peer average of 3.6x and the US biotechs industry average of 2.7x, so the market is already assigning Celldex a richer multiple than many comparables even while other metrics suggest valuation support.

Result: Price-to-book of 6.4x (OVERVALUED)

However, Celldex Therapeutics still carries clear risks, including reliance on early stage programs and ongoing losses of $283.646m, which could pressure future funding needs.

Another View on Celldex Therapeutics: Cash Flows vs Book Value

While Celldex Therapeutics looks expensive on a 6.4x P/B ratio, our DCF model points the other way, with the stock trading at $37.21 versus an estimated future cash flow value of $81.61. That gap paints a very different picture. Which signal should carry more weight for you?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Celldex Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 43 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mixed signals around Celldex Therapeutics, it makes sense to look under the hood yourself and decide how the risk and reward balance stacks up. Take a closer look at the trade off by reviewing the 2 key rewards and 3 important warning signs

Looking For More Investment Ideas Beyond Celldex Therapeutics?

You do not need to stop with Celldex Therapeutics, use the Simply Wall Street screener to quickly surface stocks that match your preferred balance of risk and return.

• Target dependable cash generators by reviewing the solid balance sheet and fundamentals stocks screener (48 results) that can help anchor a portfolio through different market conditions.
• Hunt for potential mispricings with the 43 high quality undervalued stocks and see which companies the model flags as trading below their assessed worth.
• Identify potential income streams by scanning the 10 dividend fortresses that focuses on companies with higher yields backed by robust fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.